Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE Announces Second Strike Against Gilenya For Cost-Effectiveness

This article was originally published in The Pink Sheet Daily

Executive Summary

NICE says that additional information provided by Novartis does not satisify its requirement for proof of cost-effectiveness of Gilenya.

You may also be interested in...



German HTA Assessment Knocks Back Gilenya In Europe

IQWiG’s failure to find any added benefit from Novartis’ oral MS drug Gilenya in two out of three of its target patient groups, on the grounds of insufficient evidence, puts pressure on the drug following a similarly negative recommendation by U.K. cost-watchdog NICE at the end of 2011.

Sanofi's Oral Aubagio Jostles For Position In Multiple Sclerosis Market

FDA accepts filing for teriflunomide, but concerns about pregnancy risk in a young patient population and questions about comparative efficacy could limit market potential.

Novartis' Gilenya: Down But Not Out With NICE

Novartis faces a setback in the U.K., as NICE refuses to recommend Gilenya to the NHS, citing lack of comparative data and cost.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel